Can we use MTX+MMF to treat active #TAK rather than CYC? ➡️MTX+MMF vs CYC/AZA over 52W MTX+MMF had: ⬆️Better efficacy in inducing & maintaining remission ❕Comparable safety to CYC/AZA ⏩This combination may prove preferable to using CYC Ab1696 #ACR24 @RheumNow https://t.co/S0A8YNk3qL

• https://x.com/DrMiniDey/status/1858218295322665117/photo/1

A#1691 Biomarkers for Rx response SSc ILD? 92 SSc-ILD pts, 19 had progressive pulm fibrosis (PPF) KL-6 - incr in PPF, decr in those w/o PPF CXCL-4 decr across cohort - non-signif trend for more w/o PPF Specifically in MMF: CRP, KL6, CXCL4 are predictive #ACR24 @RheumNow https://t.co/9fG6atcLmK

• https://x.com/ericdeinmd/status/1858218645949682030/photo/1
• https://x.com/ericdeinmd/status/1858218645949682030/photo/1
• https://x.com/ericdeinmd/status/1858218645949682030/photo/1

#Methotrexate is a dud in #PMR for benefit above #glucocorticoids ! #RCT MTX25mg/wk + Pred 15 Mg/d tapered to 0 at 1 yr vs #Prednisone + placebo same taper NO BENEFIT from #MTX #1697 #ACR24 @ACRheum @RheumNow As FYI Poster at #EULAR observed #Leflunomide better than #MTX https://t.co/RepBmOKIsA

• https://x.com/Janetbirdope/status/1858218884286804011/photo/1
• https://x.com/Janetbirdope/status/1858218884286804011/photo/1

Abstract 1686: Urinary proteomics reveals potential markers (MMP-13, M-CSF receptor, CD163, ALCAM, FOLR2) and pathways (neutrophil degranulation, ECM, tissue remodeling) involved in lupus nephritis Class II. @RheumNow #ACR24 https://t.co/kufd2zl9yc

• https://x.com/AkhilSoodMD/status/1858211500739199121/photo/1

@kekuchinad A#1689 PFT ref equations -> inequities in SSc ILD Predict FVC uses age, ht, sex & race - higher % pred values -> underdx Race-specific v neutral equations: More black pts meet trial eligibility (69/57%), immunos (56/40), lung t, (14/9) @RheumNow #ACR24 #ACRBest https://t.co/40PFmdk3Xv

• https://x.com/ericdeinmd/status/1858211728707686717/photo/1
• https://x.com/ericdeinmd/status/1858211728707686717/photo/1
• https://x.com/ericdeinmd/status/1858211728707686717/photo/1
• https://x.com/ericdeinmd/status/1858211728707686717/photo/1

Is there a less invasive approach to evaluate lupus nephritis? Abstract 1683 highlights the potential role of 68Ga-FAPI PET imaging in evaluating for lupus nephritis. FAPI uptake ↑ in pts with lupus nephritis vs HC. Correlated with IFN -α and IFN-γ pathways. @RheumNow #ACR24

Very neat simulated model of GC regimens in AAV pt on fixed RTX by @zach_wallace_md and co Over 5 years: - No difference in relapse btwn standard GC vs. minimal GC + avacopan - Higher DMII rates in standard group Adds to trial + real world data @RheumNow #ACR24 Abst 1598

Will my patient with lupus nephritis respond well to induction therapy? Abstract 1685: Aundhia et al demonstrate the promising utility of RAIL to predict complete renal response in patients with lupus nephritis (Class III or IV +/- V) @RheumNow #ACR24 https://t.co/JBldrrwUhN

• https://x.com/AkhilSoodMD/status/1858213010609000758/photo/1

#1689: race-neutral 🫁 function equations in SSc improve equity: 🔹 Race-specific equations underestimate disease severity in Black patients. 🔹 Switching to race-neutral reclassified 45% of Black patients to more severe, 16% of White patients to less severe @RheumNow #acr24 https://t.co/BfK2PsCMX5

• https://x.com/CaoilfhionnMD/status/1858213164443119768/photo/1

Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022 for #SLE Belimumab ~ 600% increase!! @RheumNow #ACR24 abst#1259 https://t.co/norl1xk2KF

• https://x.com/bella_mehta/status/1858205209165541866/photo/1

#SLE treatments #ACR24: Compared efficacy & safety of belimumab vs. telitacicept (targets B-lymphocyte stimulator (BLyS) and proliferation-inducing ligand(APRIL)) Both improved disease activity with no difference in efficacy Belimumab had lower infection rates @RheumNow abst1544

More data from PAISLEY, deucravacitinib in SLE Small but significant benefit w/respect to joints, a little disappointing tbh Would like to see this for all manifestations ie pericarditis, pleuritis, etc Anyone have an infographic or useful chart? #ACR20 @RheumNow Abstr#1552 https://t.co/tXUoUtssxo

• https://x.com/EBRheum/status/1858206970785706213/photo/1
• https://x.com/EBRheum/status/1858206970785706213/photo/1

Low uptake of SGLT2i in Lupus nephritis SGLT2i users had similar adverse event rates as ACEi/ARB users SGLT2i users experienced more weight loss #ACR24 @rheumnow abst#1534 https://t.co/tB5o7tyhu5

• https://x.com/bella_mehta/status/1858207474039292036/photo/1

Study on SLE and NMO overlap: Higher risk of acute cystitis & severe sepsis in hospitalized patients SLE/NMO overlap patients 3x more likely to develop acute cystitis 2x more likely to develop severe sepsis #ACR24 @RheumNow abst#1529

Study on SLE treatments: Compared adverse events of anifrolumab vs. belimumab Similar risks for mortality, sepsis, herpes zoster, dialysis, MACE, PE/VTE, COVID-19, URI, pneumonia, and mental illness #ACR24 @RheumNow abst#1527